Curia Appoints Steve Lavezoli as Vice President, Biologics

Curia’s Vice President of Biologics

ALBANY, N.Y., Feb. 23, 2024 (GLOBE NEWSWIRE) — Curia, a leading contract research, development and manufacturing organization, today announced it has appointed Steve Lavezoli as vice president of biologics effective Feb. 26. Lavezoli will lead Curia’s biologics division, overseeing its discovery, development and manufacturing services.

“This is an exciting time for our biologics team, and we are pleased to have Steve on board,” said Curia CEO Philip Macnabb. “Steve’s remarkable breadth of experience leading commercial operations for biologics development and manufacturing makes him a natural fit to lead our biologics efforts. Under his guidance, I have every confidence that we will further our mission of life-changing life science.”

Lavezoli most recently worked for Scorpius Biologics, a startup CDMO focused on microbial and mammalian biologics development and manufacturing as the vice president of commercial operations. Prior to joining Scorpius, he spent four years with Catalent Biologics, focused on drug substance business development in the U.S. for early-stage clinical programs and later focusing on late-stage commercial program integration. He also spent 12 years in the industrial gasses industry with Linde Gas before joining W.L. Gore in the startup biopharmaceutical division to work on a commercial business/market development role for bulk drug substance single-use items. He earned his B.S. in chemical engineering from Pennsylvania State University.

“Curia holds a unique position in the CDMO industry with an impressive end-to-end offering,” said Lavezoli. “It’s an honor to join a team with such deep scientific expertise and values-driven purpose to drive a positive impact on patients’ lives.”

Learn more about Curia’s biologics offerings here: https://curiaglobal.com/biologics/

About Curia
Curia is a Contract Development and Manufacturing Organization (CDMO) with over 30 years of experience, an integrated network of 27 global sites and over 3,500 employees partnering with biopharmaceutical customers to bring life-changing therapies to market. Our biologics and small molecule offerings span discovery through commercialization, with integrated regulatory and analytical capabilities. Our scientific and process experts and state-of-the-art facilities deliver best-in-class experience across drug substance and drug product manufacturing. From curiosity to cure, we deliver every step to improve patients’ lives. Visit us at curiaglobal.com.

Corporate Contact:
Viana Bhagan
Curia
+1 518 512 2111
corporatecommunications@CuriaGlobal.com

A photo accompanying this announcement is available at: https://www.globenewswire.com/NewsRoom/AttachmentNg/f9784607-495c-40d3-9e39-b65c8147d1c5

GlobeNewswire Distribution ID 9041965

Call for Entries Issued for The 21st Annual International Business Awards®

New Technology Solution Awards Categories for Artificial Intelligence

Call for Entries Issued for The 21st Annual International Business Awards®

The Stevie Awards are now accepting nominations for The 21st Annual International Business Awards®, the world’s premier business awards competition, attracting nominations from organizations in over 70 nations and territories each year.

FAIRFAX, Va., Feb. 22, 2024 (GLOBE NEWSWIRE) — The Stevie® Awards are now accepting nominations for The 21st Annual International Business Awards®, the world’s premier business awards competition, attracting nominations from organizations in over 70 nations and territories each year.

All individuals and organizations worldwide—public and private, for-profit and non-profit, large and small—may submit nominations to The International Business Awards. The early-bird entry deadline, with reduced entry fees, is 10 April. The final entry deadline is 8 May, but late entries will be accepted through 12 June with payment of a late fee. Entry details are available at www.StevieAwards.com/IBA.

Juries featuring more than 150 executives worldwide will determine the Gold, Silver, and Bronze Stevie Award winners. Winners will be announced on 14 August and celebrated at a gala banquet in Europe this October (date and location to be confirmed).

The 21st Annual International Business Awards® are Accepting Nominations

The International Business Awards recognize achievement in every facet of the workplace. Categories include:

There are many new and revised features of The International Business Awards for 2024:

  • There are a variety of new Technology Solution Categories for Artificial Intelligence and Machine Learning Solutions, split into subcategories for Financial, Generative (audio, graphics, text, video), Healthcare, and other solutions. There are additional new technology categories for Cybersecurity, Digital Asset Management, Digital Employee Experience, and Knowledge Center/Help Sites.
  • There are many new Event Categories for Cause & Green Events including CSR Experience, Employee Giving & Volunteerism, Inclusive Events, and other Brand Experiences/Events by type including Gamified Experience, Pop-Up Experience, and Immersive Experience.
  • There are new categories sprinkled throughout the category groups for New Product & Product Management Awards, Mobile Site & App Awards, and Website Awards.

Stevie Award winners in the 2023 IBAs included Ayala Land Inc. (Philippines), Anexa BPO (Mexico), Empire Eagle Food (Taiwan), EY Global Services Limited (USA), IBM Corporation (Worldwide), LLYC (Spain), Ooredoo Group (Qatar), Saudi Aramco (Saudi Arabia), TalkLife (United Kingdom), Turkish Aerospace (Turkey), HALKBANK (Turkey), The Dubai Digital Authority (United Arab Emirates), Viettel Group (Vietnam), and many more.

About the Stevie Awards
Stevie Awards are conferred in eight programs: the Asia-Pacific Stevie Awards, the German Stevie Awards, the Middle East & North Africa Stevie Awards, The American Business Awards®, The International Business Awards®, the Stevie Awards for Great Employers, the Stevie Awards for Women in Business, and the Stevie Awards for Sales & Customer Service. Stevie Awards competitions receive more than 12,000 entries each year from organizations in more than 70 nations. Honoring organizations of all types and sizes and the people behind them, the Stevies recognize outstanding performances in the workplace worldwide. Learn more about the Stevie Awards at http://www.StevieAwards.com.

Contact:
Nina Moore
+1 (703) 547-8389
Nina@StevieAwards.com

A photo accompanying this announcement is available at https://www.globenewswire.com/NewsRoom/AttachmentNg/bfd82c2d-0486-47b4-8122-630fc25eb97c

GlobeNewswire Distribution ID 9040884

Lantronix Announces Percepxion™, Its New Cloud Software Platform for IoT Devices

Percepxion™ comes pre-configured in Lantronix’s gateways, routers, trackers and switches to accelerate IoT edge device deployments

IRVINE, Calif., Feb. 21, 2024 (GLOBE NEWSWIRE) — Lantronix Inc. (NASDAQ: LTRX), a global provider of compute and connectivity IoT solutions, today announced Percepxion™, its new Cloud IoT Edge Solutions platform. Percepxion is pre-configured into Lantronix’s award-winning IoT gateways, routers, trackers and switches to provide secure, comprehensive device lifecycle management. The Percepxion platform efficiently scales edge deployments from regional to global and is managed through an intuitive single pane of glass.

“The Percepxion platform provides our customers with an easy-to-deploy IoT solution that comes pre-configured on our connect and compute products,” said Jacques Issa, vice president of Marketing at Lantronix Inc. “Percepxion’s multi-tenant feature enables a B2B solution, generating incremental revenue streams for our end customers.”

Remote installation of Lantronix devices includes zero-touch automated provisioning managed through Percepxion. Site-required firmware, configuration and certificates are remotely loaded to ensure secure data communication and compliant devices. It is ideal for critical infrastructure management, fleet management, smart cities and other end-to-end IoT edge solutions.

Key Percepxion features include:

  • Robust Security. Percepxion simplifies software updates for maintaining robust device cybersecurity. The cloud platform complies with complex security requirements from corporate security offices for devices, data access and users, ensuring integrity and confidentiality across entire solutions.
  • Real-Time Device Operation. Percepxion enables real-time remote access for diagnosing and troubleshooting as well as over-the-air updates with select grouping and automated monitoring that generate alerts and notifications to minimize system downtime.
  • Powerful Data Integration and Analysis. Percepxion’s custom dashboards provide on-demand visibility of device telemetry data. Trend analysis provides edge insights to improve efficiency and create predictive maintenance applications. Enterprise use cases can access data using Percepxion API services for headless operation.

Percepxion’s holistic approach to IoT edge solutions accelerates time to revenue by simplifying edge management and maintenance while providing customers with assistance and long-term assurance.

The Percepxion Service for Lantronix Devices

Delivered as a service, the Percepxion multi-tenant cloud platform provides businesses with comprehensive device lifecycle management through Web and mobile apps. It is offered with bundled Level Technical Support, limited warranty and other optional services

To learn more about Percepxion and review the 60-day free trial offer, visit https://www.lantronix.com/percepxion/.

About Lantronix

Lantronix Inc. is a global provider of compute and connectivity IoT solutions that target high-growth industries including Smart Cities, Automotive and Enterprise. Lantronix’s products and services empower companies to achieve success in the growing IoT markets by delivering customizable solutions that address each layer of the IoT Stack. Lantronix’s leading-edge solutions include Intelligent Substations infrastructure, Infotainment systems and Video Surveillance, supplemented with advanced Out-of-Band Management (OOB) for Cloud and Edge Computing.

For more information, visit the Lantronix website.

“Safe Harbor” Statement under the Private Securities Litigation Reform Act of 1995: Any statements set forth in this news release that are not entirely historical and factual in nature, including without limitation statements related to our solutions, technologies and products and expectations regarding our management and our future growth and profitability. These forward-looking statements are based on our current expectations and are subject to substantial risks and uncertainties that could cause our actual results, future business, financial condition, or performance to differ materially from our historical results or those expressed or implied in any forward-looking statement contained in this news release. The potential risks and uncertainties include, but are not limited to, such factors as the effects of negative or worsening regional and worldwide economic conditions or market instability on our business, including effects on purchasing decisions by our customers; our ability to mitigate any disruption in our and our suppliers’ and vendors’ supply chains due to the COVID-19 pandemic or other outbreaks, wars and recent tensions in Europe, Asia and the Middle East, or other factors; future responses to and effects of public health crises; cybersecurity risks; changes in applicable U.S. and foreign government laws, regulations, and tariffs; our ability to successfully implement our acquisitions strategy or integrate acquired companies; difficulties and costs of protecting patents and other proprietary rights; the level of our indebtedness, our ability to service our indebtedness and the restrictions in our debt agreements; and any additional factors included in our Annual Report on Form 10-K for the fiscal year ended June 30, 2023, filed with the Securities and Exchange Commission (the “SEC”) on Sept. 12, 2023, including in the section entitled “Risk Factors” in Item 1A of Part I of such report, as well as in our other public filings with the SEC. Additional risk factors may be identified from time to time in our future filings. The forward-looking statements included in this release speak only as of the date hereof, and we do not undertake any obligation to update these forward-looking statements to reflect subsequent events or circumstances.

© 2024 Lantronix, Inc. All rights reserved. Lantronix is a registered trademark. Other trademarks and trade names are those of their respective owners.

Lantronix Media Contact:
Gail Kathryn Miller
Corporate Marketing &
Communications Manager
media@lantronix.com
949-212-0960

Lantronix Analyst and Investor Contact:
Jeremy Whitaker
Chief Financial Officer
investors@lantronix.com
949-450-7241

GlobeNewswire Distribution ID 9041031

Fortrea Increases Patient Access Capabilities and Cold Chain Expertise with FortreaRx™ Expansion

Fortrea’s non-commercial specialty pharmacy expansion delivers flexible, scalable solutions to customers and life-changing medications direct to patients

DURHAM, N.C., Feb. 20, 2024 (GLOBE NEWSWIRE) — Fortrea (Nasdaq: FTRE) (the “Company”), a leading global contract research organization (CRO), today announced the opening of its expanded non-commercial specialty pharmacy, FortreaRx™, located in Lake Mary, Florida, which offers advanced patient access solutions across the United States, including ambient and cold-chain distribution capabilities and expertise.

Licensed in all 50 states and U.S. territories, FortreaRx delivers flexible, scalable solutions that meet the specific needs of its customers while providing medications to patients who may otherwise not have access to them. Non-commercial specialty pharmacies, like FortreaRx, provide these solutions on behalf of their pharmaceutical manufacturer customers and are uniquely positioned to serve as a bridge between pharmaceutical manufacturers and patients who meet the manufacturer requirements for prescription assistance.

Since FortreaRx’s inception in late 2008, Fortrea has pioneered non-commercial specialty pharmacy services, focusing exclusively on the distribution of free-goods products as an integrated component of pharmaceutical manufacturer-sponsored patient assistance programs (PAP) designed to expand access to therapy for qualified patients with no health insurance or those who are underinsured. The FortreaRx 40,000-square-foot facility doubles its operational space and bolsters its capabilities, delivering:

  • 1,800 square feet of ambient storage
  • 6,000+ square feet of cold chain storage with more than 85 percent of prescriptions filled by FortreaRx requiring this unique handling
  • Greater processing and fulfillment space for up to 18,000 prescriptions daily
  • Enhanced shipping solutions with options for overnight, expedited and 2-day deliveries

“Fortrea’s well-established patient services offerings, combined with the expanded capabilities of FortreaRx, deliver an end-to-end approach, from early clinical stages to post-market delivery, ensuring a comprehensive and personalized experience for patients,” said Bill Nolan, vice president and global head of Patient Access at Fortrea. “From our expertise in broad-range disease states to our unwavering commitment to patient assistance, Fortrea excels at delivering timely and impactful solutions to our pharmaceutical sponsors that strive to reduce patient and provider challenges by streamlining enrollment processes and by offering full integration with broader patient support initiatives.”

FortreaRx’s call center hub of case managers seamlessly manages patient inquiries, counseling and data verification of prescriptions. Fortrea’s patient access team helps patients and providers understand and navigate the complexities of coverage while removing obstacles to get medication to patients.

FortreaRx delivers efficient, consultative and cost-effective solutions for manufacturer prescription programs typically resulting in significant yearly savings for patients.

For more information about FortreaRx and its services, please visit Fortrea.com.

About Fortrea

Fortrea (Nasdaq: FTRE) is a leading global provider of clinical development and patient access solutions to the life sciences industry. We partner with emerging and large biopharmaceutical, medical device and diagnostic companies to drive healthcare innovation that accelerates life changing therapies to patients in need. Fortrea provides phase I-IV clinical trial management, clinical pharmacology, differentiated technology-enabled trial solutions and post-approval services. Fortrea’s solutions leverage three decades of experience spanning more than 20 therapeutic areas, a passion for scientific rigor, exceptional insights and a strong investigator site network. Our talented and diverse team of about 19,000 people working in more than 90 countries is scaled to deliver focused and agile solutions to customers globally. Learn more about how Fortrea is becoming a transformative force from pipeline to patient at Fortrea.com and follow us on LinkedIn and X (formerly Twitter) @Fortrea.

Fortrea Contacts:
Fortrea Media: Galen Wilson – 703-298-0802, media@fortrea.com
Fortrea Media: Kate Dillon – 646-818-9115, kdillon@prosek.com

GlobeNewswire Distribution ID 9040223

Axi Select hailed as the future of prop trading as multiple demo account firms close doors due to pressures from regulators, brokers, and tech providers

Axi Select

Axi Select hailed as the future of prop trading as multiple demo account firms close doors due to pressures from regulators, brokers, and tech providers

SYDNEY, Australia, Feb. 20, 2024 (GLOBE NEWSWIRE) — Bucking the trend of recent negative developments in the prop firm industry, leading global CFD and FX broker Axi, which launched Axi Select – their unique capital allocation programme for talented traders – has been hailed by many industry experts as the future of the industry.

Recent issues experienced in the prop trading industry have resulted in multiple firms having to pause or close down their service due to pressure from regulators, partner brokers or tech providers.

Axi Select is completely different to the industry, and as a result has legitimised the prop firm model by offering a live trading account programme, with real controls in terms of execution, transparency, and fair market conditions. Since its launch in mid-2023, Axi Select has witnessed an incredible 40% month-on-month increase in the number of active clients on their platforms.

Axi believes their Select programme is revolutionary, sustainable and is the future of the prop firm model. Greg Rubin, Head of Axi Select, stated “In the last week the prop trading industry has been turned on its head completely with multiple firms having to suspend their services due to external pressures.

“We foresaw this, which is why we’ve developed a capital allocation programme which is built on our live trading account model and has been available in over 100 countries for more than 16 years. This has given us the confidence that Axi Select is a long-term solution to the prop trading community, and not subject to the issues now faced by prop firms who offer the demo account registration fee model and are under constant pressure from regulators and their tech partners.”

He continued “We genuinely empathise with the thousands of talented traders who will now be denied access to their allocated funds, and we encourage anyone using the demo trading registration model to question whether their prop firm partner will be able to continue as an ongoing concern given recent events. Unfortunately, this could be the beginning of the end for the demo account prop firm model.”

Axi Select offers a very attractive funding model – $1 million USD top allocation and clients can keep up to 90% of their profits – that’s one of the top allocation offerings worldwide, from an award-winning globally recognised, respected, and trusted broker.

By joining Axi you don’t need to pay a registration fee. Yes, you need to fund your trading account, but that money is yours to withdraw at any time and any profits you make on your funded account, you keep in addition to funds allocated by Axi.

“We believe passionately that Axi Select is the best allocation programme globally” said Rajesh Yohannan, Group CEO of Axi.

“By using a live trading account, with real money and the emotions that accompany this, we believe you are more likely to be profitable longer term and make money from your own live account as well as the funded proportion. Our Axi Select account has all the controls we offer to our live account holders globally. This includes access to our award-winning fast, transparent, and fair-trade execution.”

He added “If you are a talented trader and are looking for a legitimate funding programme which is designed to truly help you succeed and profit from the financial markets, and you want the stability of an account model which has been in market for 16 years, then Axi Select is the place for you to find your Edge.”

About Axi Select*

Axi Select* is a unique capital allocation programme that was specifically designed to help you succeed as a professional trader. Axi Select* offers a generous funding of up to $1 million USD as part of a structured and fair pathway to help you meet your long-term and most ambitious trading aspirations. Solidify your trading skills, knowledge and understanding of the markets and embark on your biggest trading journey ever with Axi through Axi Select.

Why Axi Select*?

  • 100% Free to join – No registration fees
  • Earn 90% of profits on $1,000,000 USD of our funds
  • Unrestrictive trading conditions & a structured pathway that provides a fair & real opportunity for traders to become professional traders
  • Trading score (Edge score) to assess & assist with trading performance
  • Dashboard with analytics, advanced stats, and a leader board
  • Exclusive online trading room with live analysis and learning videos from professional traders. Ability to interact with fellow traders and share analysis/trading ideas.
  • Trustworthy broker with over 35+ industry awards.

Axi

How is Axi Select* different from other programmes?

Programme Axi Select Industry Standard
Registration fee No Yes
Pass Evaluation No Yes
Restrictive Trading Conditions No Varies
Number of Attempts 3 1
Leverage 100:1 Varies, majority less than 100:1
Account Type Real Trading Account Demo
Additional Tools Dashboard/Leaderboard, Edge Score, Trading Room Varies

Learn more & switch to Axi Select: https://www.axi.com/select

* The Axi Select programme is only available to clients of AxiTrader Limited. CFDs carry a high risk of investment loss. In our dealings with you, we will act as a principal counterparty to all of your positions. This content is not available for AU, NZ, EU, and UK residents. For more information, refer to our Terms of Service. Other fees and minimum deposit apply.

About Axi

Axi is a global online FX and CFD trading company, trusted by thousands of ambitious customers in 100+ countries around the world. We help all types of traders, trading businesses, banks and financial organizations find the edge they need to achieve their financial goals through informed transactions made on the world’s financial markets. Axi offers a wide range of assets including CFDs for several asset classes including Forex, Shares, Gold, Silver, Oil, Coffee, Indices, and other commodities.

At Axi, we are proud of our reputation as an honest, fair, and trusted broker. Our many awards and ‘Great’ Trustpilot reviews prove we have earned the confidence of customers who value our outstanding service, fast execution, secure payments, segregated funds, and easy withdrawals.

For further enquiries contact service@axi.com

A photo accompanying this announcement is available at https://www.globenewswire.com/NewsRoom/AttachmentNg/4b7f4608-f090-471c-995d-de6c0f23438e

GlobeNewswire Distribution ID 1000914826